Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1K/DOCA/salt-induced hypertension.

Yifang LiMatthew ShenDorota FerensBrad R S BroughtonPadma MurthiSheetal SainiRobert E WiddopSharon D RicardoAnita A PinarChrishan S Samuel

Published in: British journal of pharmacology (2021)

Combining BM-MSCs and serelaxin provided broader renoprotection over either therapy alone or perindopril and might represent a novel treatment for hypertensive CKD.

Keyphrases

mesenchymal stem cells
blood pressure
umbilical cord
chronic kidney disease
hypertensive patients
bone marrow
diabetic rats
high glucose
arterial hypertension
cell therapy